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Fig 1. Palifermin-associated papules. On the back of
patient’s forearms and hands were scattered 3- to 5-mm,
flesh-colored, flat-topped papules without scale.
Fig 2. Palifermin-associated papules. Slightly mamillated
epidermis with acanthosis, hypergranulosis, and mild
keratinocytic atypia of the basal and lower spinous layers.
(Hematoxylin-eosin stain; original magnification: 3100.)
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Papular eruption associated with palifermin
To the Editor: A 52-year-old man with nasal-type
extranodal natural killer T-cell lymphoma presented
with a 2-day history of scattered faintly erythematous
and skin-colored papules on the back of the neck
and bilateral upper extremities. He noted mild pru-
ritus associated with these lesions. Three days before
the eruption, the patient began treatment as an
inpatient with palifermin as mucositis prophylaxis
for chemotherapy and autologous stem cell
transplantation. Physical examination was notable
for scattered flat-topped erythematous papules on
the back of the neck, back of the hands, and
forearms (Fig 1). Examination of the oral mucosa
was unremarkable. A shave biopsy specimen
obtained from the back of the left hand (Fig 2)
revealed a slightly mamillated epidermis with
acanthosis, hypergranulosis, and mild keratinocytic
atypia of the basal and lower spinous layers.
The patient was given the diagnosis of a
palifermin-associated papular eruption and was
given triamcinolone acetonide for relief of pruritus.
Palifermin is a recombinant, N-truncated version
of human keratinocyte growth factor with similar
binding properties but increased stability. It is
Food and Drug Administration approved for
reducing the incidence and duration of severe
oral mucositis in patients with hematologic
malignancies receiving chemotherapy, radiotherapy,
and hematopoietic stem cell transplantation.1
Palifermin is administered intravenously at a dose
Open access under CC BY-NC-ND license.of 60 g/kg/d for 3 consecutive days before radiation
therapy and 3 consecutive days after stem cell
transplantation.1 The average cost of palifermin
for a 70-kg patient is approximately $10,000.1
Adverse cutaneous reactions to palifermin in early
clinical trials were described as ‘‘rash,’’ ‘‘erythema,’’
or ‘‘pruritus’’ and were noted in 55%, 44%, and 50%
of treated patients, respectively.1,2 Other mucocuta-
neous reactions, including thickening and whitening
of the tongue, oral and flexural hyperpigmentation
or erythema, acanthosis nigricanselike eruptions,
palmoplantar erythrodysesthesia, and intertriginous
papular eruptions have since been described in the
literature.2-6
Our patient’s presentation most closely resembles
cases of flexural lichenoid or verruca planaelike
papular eruptions associated with palifermin.
One report describes a patient with multiple
myeloma who developed intertriginous erythema
and a papular eruption of the neck, trunk, and
extremities 1 day after completing a 3-day course
of palifermin.2 In situ hybridization to test for human
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whereas staining with the proliferation markers
Ki-67 and cytokeratin 5/6 showed dramatically
increased labeling of basilar and suprabasilar kera-
tinocytes. Another report described 5 patients with
intertriginous erythema and hyperpigmented pap-
ules that began 7 to 30 days after the first palifermin
dose. Pathology revealed a prominent granular layer
with coarse granules in biopsy samples, features also
seen in our case. In addition, they demonstrate
up-regulation of filaggrin, a well-described effect of
keratinocyte growth factor.6
Although our patient’s eruption was not
predominantly intertriginous, the timing, clinical
morphology, and histopathologic findings are
consistent with palifermin-associated papules.
Based on immunohistochemical studies performed
in the aforementioned cases, it seems reasonable
to conclude with those investigators that the
papular eruption is likely a result of palifermin’s
proliferative effect on epithelial tissues.2,6 The
vast majority of cutaneous reactions caused by
palifermin have been benign, minimally symptom-
atic, and self-limited, with resolution of lesions soon
after stopping the medication. Three days after
completion of palifermin, our patient already
demonstrated partial regression of the lesions,
although we did recommend a mid-potency topical
corticosteroid for relief of pruritus that improved his
symptoms.
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A 52-year-old man with bullous pemphigoid
and bullous cystitis
To the Editor: A 52-year-old man with a medical
history of psoriasis and bullous pemphigoid (BP)
presented with a flare of his BP (Fig 1), which
was first diagnosed in 2003 and confirmed by
indirect immunofluorescence on salt-split skin. On
examination, he had erosions and bullae on the
bilateral lower extremities without evidence of
oral or anogenital mucosal involvement. In
addition, the patient stated that he recently had
a cystoscopy with bladder biopsies for ongoing
dysuria, frequency, and microhematuria, which
started 10 months prior. On cystoscopy, the
bladder was noted to have numerous bullae.
Biopsy specimen was obtained of the perilesional
epithelium in the bladder, which demonstrated
numerous eosinophils and a subepithelial split
(Fig 2). At the time of the cystoscopy, he was not
taking any medications that could account for the
bladder inflammation nor did his urinalysis or
urine culture show evidence of infection. Because
of previous resolution of his BP with Enbrel (as
was initially prescribed for his psoriasis), the
patient was restarted on Enbrel (50 mg) twice
weekly for 3 months to be used in conjunction
with clobetasol 0.05% ointment twice daily. At his
follow-up appointment 4 months later, his BP was
clear and his urologic symptoms had completely
abated.
To our knowledge, symptomatic involvement of
the bladder in BP has not been described to
date; however, expression of BP180 has been
demonstrated in the transitional epithelium of
the bladder by indirect immunofluorescence.1 In
addition, BP230 has been demonstrated by
immunofluorescence in rat bladder tumor cell line.2
Despite this, the only bladder involvement in BP was
demonstrated in asymptomatic patients based on
